CONIFER, CO--(Marketwire - September 25, 2008) - Xpention Genetics, Inc. (OTCBB: XPNG) recently signed a contract with AbD Serotec, a subsidiary of MorphoSys AG, one of the world's leading antibody technology companies, to develop custom recombinant monoclonal antibodies for revalidating and updating the p65 cancer detection test. The first two phases of the contract, p65 gene synthesis and expression, were recently successfully completed. The next phase of the contract has been initiated and is directed at finding high affinity binders to p65. Upon completion, binders with assay potential will be delivered to us for p65 assay revalidation.
